BRPI0919777A2 - derivados de peptídeo e uso dos mesmos como vetores para moléculas na forma de conjugados - Google Patents

derivados de peptídeo e uso dos mesmos como vetores para moléculas na forma de conjugados

Info

Publication number
BRPI0919777A2
BRPI0919777A2 BRPI0919777A BRPI0919777A BRPI0919777A2 BR PI0919777 A2 BRPI0919777 A2 BR PI0919777A2 BR PI0919777 A BRPI0919777 A BR PI0919777A BR PI0919777 A BRPI0919777 A BR PI0919777A BR PI0919777 A2 BRPI0919777 A2 BR PI0919777A2
Authority
BR
Brazil
Prior art keywords
conjugates
vectors
molecules
peptide derivatives
peptide
Prior art date
Application number
BRPI0919777A
Other languages
English (en)
Inventor
Marion David
Michel Khrestchatiski
Patrick Vlieghe
Yves Molino
Original Assignee
Centre Nat Rech Scient
Univ Aix Marseille Ii
Vect Horus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Aix Marseille Ii, Vect Horus filed Critical Centre Nat Rech Scient
Publication of BRPI0919777A2 publication Critical patent/BRPI0919777A2/pt
Publication of BRPI0919777B1 publication Critical patent/BRPI0919777B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0919777-0A 2008-10-22 2009-10-20 Derivados de peptídeo e uso dos mesmos como vetores para moléculas na forma de conjugados BRPI0919777B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0857159A FR2937322B1 (fr) 2008-10-22 2008-10-22 Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR0857159 2008-10-22
PCT/FR2009/051991 WO2010046588A1 (fr) 2008-10-22 2009-10-20 Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues

Publications (2)

Publication Number Publication Date
BRPI0919777A2 true BRPI0919777A2 (pt) 2016-09-20
BRPI0919777B1 BRPI0919777B1 (pt) 2021-09-14

Family

ID=40852530

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919777-0A BRPI0919777B1 (pt) 2008-10-22 2009-10-20 Derivados de peptídeo e uso dos mesmos como vetores para moléculas na forma de conjugados

Country Status (16)

Country Link
US (2) US8729029B2 (pt)
EP (1) EP2350117B1 (pt)
JP (2) JP5808250B2 (pt)
CN (1) CN102282159B (pt)
AU (1) AU2009306237B2 (pt)
BR (1) BRPI0919777B1 (pt)
CA (1) CA2741098C (pt)
DK (1) DK2350117T3 (pt)
EA (1) EA022976B1 (pt)
ES (1) ES2525649T3 (pt)
FR (1) FR2937322B1 (pt)
HR (1) HRP20141139T1 (pt)
PL (1) PL2350117T3 (pt)
SI (1) SI2350117T1 (pt)
WO (1) WO2010046588A1 (pt)
ZA (1) ZA201103669B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60138535D1 (de) 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
FR2937322B1 (fr) * 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) * 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
KR101742346B1 (ko) 2010-04-23 2017-06-15 시나게바 바이오파르마, 코포레이션 리소솜 축적병 효소
BR122019021757B1 (pt) 2010-09-09 2020-12-08 Alexion Pharmaceuticals, Inc composição farmacêutica para tratamento de um paciente humano sofrendo de uma deficiência de lipase ácida lisossomal (lal)
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
PL2908837T3 (pl) * 2012-10-19 2019-08-30 Vect-Horus Kompozycje do dostarczania leku
CN104117069A (zh) * 2013-04-26 2014-10-29 复旦大学 一种针对脑胶质瘤的靶向纳米递药系统及其制备方法和应用
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP2896402A1 (en) * 2014-01-20 2015-07-22 Vect-Horus Activated neurotensin molecules and the uses thereof
US10040831B2 (en) 2016-12-19 2018-08-07 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CA3049508A1 (en) * 2017-01-30 2018-08-02 Vect-Horus Compositions and methods for cancer imaging and radiotherapy
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
EP3908608A1 (en) 2019-01-09 2021-11-17 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses
WO2021116079A1 (en) 2019-12-10 2021-06-17 Université de Mons Peptides binding to ldl-receptor as carriers for crossing the blood brain barrier
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
WO2024026468A2 (en) * 2022-07-28 2024-02-01 Ohio State Innovation Foundation Methods and compositions regarding cyclic peptides for use with antibodies and antibody fragments
WO2024228936A1 (en) * 2023-05-03 2024-11-07 Merck Sharp & Dohme Llc Cyclic peptides as pet imaging agents of granzyme b
CN121969643A (zh) 2023-06-22 2026-05-01 维克塔-霍洛斯公司 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗神经系统疾病的用途
EP4480965A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
WO2025193680A1 (en) * 2024-03-11 2025-09-18 Ohio State Innovation Foundation Disulfide cyclic cell-penetrating peptides and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US6232287B1 (en) * 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
WO1999047566A1 (en) * 1998-03-17 1999-09-23 The Uab Research Foundation Synthetic peptides that enhance ldl uptake
WO2001047944A2 (en) * 1999-12-28 2001-07-05 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
JP2004520803A (ja) 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
NO20026285D0 (no) * 2002-12-30 2002-12-30 Amersham Health As Nye peptider
WO2005044224A2 (en) * 2003-05-02 2005-05-19 Case Western Reserve University Drug delivery system based on polymer nanoshells
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US7723474B2 (en) * 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
GB0404374D0 (en) * 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
FR2889532B1 (fr) 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl
US8252338B2 (en) * 2005-11-10 2012-08-28 The Regents Of The University Of California Synthetic LDL as targeted drug delivery vehicle
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations

Also Published As

Publication number Publication date
AU2009306237A1 (en) 2010-04-29
WO2010046588A1 (fr) 2010-04-29
EP2350117B1 (fr) 2014-09-10
CN102282159A (zh) 2011-12-14
CA2741098A1 (fr) 2010-04-29
DK2350117T3 (en) 2014-12-08
EA022976B1 (ru) 2016-04-29
EP2350117A1 (fr) 2011-08-03
FR2937322B1 (fr) 2013-02-22
HRP20141139T1 (en) 2015-03-13
SI2350117T1 (sl) 2015-03-31
US20110230416A1 (en) 2011-09-22
BRPI0919777B1 (pt) 2021-09-14
JP2015212264A (ja) 2015-11-26
JP2012506407A (ja) 2012-03-15
US8729029B2 (en) 2014-05-20
WO2010046588A9 (fr) 2010-06-24
JP5808250B2 (ja) 2015-11-10
CA2741098C (fr) 2017-03-28
CN102282159B (zh) 2015-11-25
PL2350117T3 (pl) 2015-04-30
ES2525649T3 (es) 2014-12-26
AU2009306237B2 (en) 2015-04-09
EA201170587A1 (ru) 2012-05-30
US9328143B2 (en) 2016-05-03
FR2937322A1 (fr) 2010-04-23
JP6232396B2 (ja) 2017-11-15
US20140243499A1 (en) 2014-08-28
ZA201103669B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
ZA201103669B (en) Peptide derivatives and use thereof as carriers for molecules in the form of conjugates
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI0822366A2 (pt) Material de tecido para uso em um artigo absorvente
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
BRPI0906739A2 (pt) Métodos e composições relacionadas para internalizar peptídeos de rgd
BRPI0913707A2 (pt) "artigo e métodos para preparação do artigo"
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0914595A2 (pt) material substituto de madeira e seu uso
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BR112012004088A2 (pt) processos para dissociação de moléculas alvo e sistema para uso no mesmo
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BRPI0916630A2 (pt) composições para uso em construção e processo de aplicação das mesmas
BR112013008410A2 (pt) sistema para uso em reparação tecidual
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0814963A2 (pt) Pró-fármacos de dipeptóides e seu uso
BRPI0906444A2 (pt) Compostos de 4-piridinona e seu uso para câncer
IL215455B (en) Methods and materials for delivering molecules
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BR112013001423A2 (pt) método, método in vitro, uso e kit útil para realizar o método
BRPI0910852A2 (pt) composições contendo lipídios e métodos de uso das mesmas
BRPI0920355A2 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina
IT1398268B1 (it) Glicerosomi e loro impiego in preparazioni farmaceutiche e cosmetiche per uso topico

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UNIVERSITE D'AIX - MARSEILLE (FR)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.